ASCO 2016 – update colorectal liver metastases View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-01-17

AUTHORS

Klaus Kaczirek

ABSTRACT

This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM. In the setting of CLM deemed initially unresectable, a phase 2 study reported superior outcomes in terms of liver metastases resection rates as well as overall survival (OS) in patients receiving a chemotherapy triplet (FOLFIRINOX) plus a targeted agent as compared to FOLFIRI or FOLFOX4 with the same targeted therapy. Finally, a study suggested that tailoring first-line chemotherapy according to TYMS-3'UTR and ERCC1-118 polymorphism status results in higher response rates and longer progression-free survival (PFS) as well as OS. More... »

PAGES

103-105

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12254-016-0308-y

DOI

http://dx.doi.org/10.1007/s12254-016-0308-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037549049

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28725278


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgery and Center for Perioperative Medicine, Medical University of Vienna, Waehringer Guertel 18\u201320, 1090 Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery and Center for Perioperative Medicine, Medical University of Vienna, Waehringer Guertel 18\u201320, 1090 Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaczirek", 
        "givenName": "Klaus", 
        "id": "sg:person.01163404744.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163404744.70"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2017-01-17", 
    "datePublishedReg": "2017-01-17", 
    "description": "This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a\u00a0large registry study, small, upfront resectable, solitary CLM should be resected using a\u00a0parenchymal sparing technique. A\u00a0prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM. In the setting of CLM deemed initially unresectable, a\u00a0phase 2\u00a0study reported superior outcomes in terms of liver metastases resection rates as well as overall survival (OS) in patients receiving a\u00a0chemotherapy triplet (FOLFIRINOX) plus a\u00a0targeted agent as compared to FOLFIRI or FOLFOX4 with the same targeted therapy. Finally, a\u00a0study suggested that tailoring first-line chemotherapy according to TYMS-3'UTR and ERCC1-118 polymorphism status results in higher response rates and longer progression-free survival (PFS) as well as OS.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12254-016-0308-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1039716", 
        "issn": [
          "1865-5041", 
          "2523-2932"
        ], 
        "name": "memo - Magazine of European Medical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "colorectal liver metastases", 
      "progression-free survival", 
      "overall survival", 
      "liver metastases", 
      "solitary colorectal liver metastases", 
      "resectable colorectal liver metastases", 
      "longer progression-free survival", 
      "large registry study", 
      "parenchymal-sparing technique", 
      "prospective noninterventional study", 
      "first-line chemotherapy", 
      "VEGF antibody bevacizumab", 
      "high response rate", 
      "noninterventional study", 
      "resection rate", 
      "congress abstracts", 
      "registry study", 
      "antibody bevacizumab", 
      "sparing techniques", 
      "Clinical Oncology", 
      "polymorphism status", 
      "response rate", 
      "superior outcomes", 
      "American Society", 
      "chemotherapy", 
      "patients", 
      "metastasis", 
      "phase 2", 
      "survival", 
      "Annual Meeting", 
      "FOLFIRI", 
      "FOLFOX4", 
      "bevacizumab", 
      "therapy", 
      "relevant data", 
      "study", 
      "oncology", 
      "ERCC1", 
      "TYMS", 
      "outcomes", 
      "borderline", 
      "rate", 
      "status", 
      "review", 
      "short review", 
      "agents", 
      "setting", 
      "update", 
      "meeting", 
      "data", 
      "Abstract", 
      "technique", 
      "society", 
      "relevant scenarios", 
      "terms", 
      "triplet", 
      "scenarios", 
      "borderline resectable CLM", 
      "setting of CLM", 
      "liver metastases resection rates", 
      "metastases resection rates", 
      "chemotherapy triplet"
    ], 
    "name": "ASCO 2016 \u2013 update colorectal liver metastases", 
    "pagination": "103-105", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037549049"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12254-016-0308-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28725278"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12254-016-0308-y", 
      "https://app.dimensions.ai/details/publication/pub.1037549049"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_733.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12254-016-0308-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12254-016-0308-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12254-016-0308-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12254-016-0308-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12254-016-0308-y'


 

This table displays all metadata directly associated to this object as RDF triples.

124 TRIPLES      21 PREDICATES      88 URIs      80 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12254-016-0308-y schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nee9675fd0802459680beb33c29bdcb51
4 schema:datePublished 2017-01-17
5 schema:datePublishedReg 2017-01-17
6 schema:description This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM. In the setting of CLM deemed initially unresectable, a phase 2 study reported superior outcomes in terms of liver metastases resection rates as well as overall survival (OS) in patients receiving a chemotherapy triplet (FOLFIRINOX) plus a targeted agent as compared to FOLFIRI or FOLFOX4 with the same targeted therapy. Finally, a study suggested that tailoring first-line chemotherapy according to <i>TYMS-3'UTR</i> and <i>ERCC1-118</i> polymorphism status results in higher response rates and longer progression-free survival (PFS) as well as OS.
7 schema:genre article
8 schema:inLanguage en
9 schema:isAccessibleForFree true
10 schema:isPartOf N5a5d2af4bd6b4cc6a06143dff2079cb6
11 N871f6be502954d13a9f9cc656f6ac322
12 sg:journal.1039716
13 schema:keywords Abstract
14 American Society
15 Annual Meeting
16 Clinical Oncology
17 ERCC1
18 FOLFIRI
19 FOLFOX4
20 TYMS
21 VEGF antibody bevacizumab
22 agents
23 antibody bevacizumab
24 bevacizumab
25 borderline
26 borderline resectable CLM
27 chemotherapy
28 chemotherapy triplet
29 colorectal liver metastases
30 congress abstracts
31 data
32 first-line chemotherapy
33 high response rate
34 large registry study
35 liver metastases
36 liver metastases resection rates
37 longer progression-free survival
38 meeting
39 metastases resection rates
40 metastasis
41 noninterventional study
42 oncology
43 outcomes
44 overall survival
45 parenchymal-sparing technique
46 patients
47 phase 2
48 polymorphism status
49 progression-free survival
50 prospective noninterventional study
51 rate
52 registry study
53 relevant data
54 relevant scenarios
55 resectable colorectal liver metastases
56 resection rate
57 response rate
58 review
59 scenarios
60 setting
61 setting of CLM
62 short review
63 society
64 solitary colorectal liver metastases
65 sparing techniques
66 status
67 study
68 superior outcomes
69 survival
70 technique
71 terms
72 therapy
73 triplet
74 update
75 schema:name ASCO 2016 – update colorectal liver metastases
76 schema:pagination 103-105
77 schema:productId N0d25cca812d44d349cb08de656b68758
78 N12c4eaa62b964dbab130687f9f13dc85
79 Ne22c885844414e4abc0656bf248a3ffd
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037549049
81 https://doi.org/10.1007/s12254-016-0308-y
82 schema:sdDatePublished 2021-11-01T18:30
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher N5f0d8f39944b464781ad1ba9c5ebcc85
85 schema:url https://doi.org/10.1007/s12254-016-0308-y
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N0d25cca812d44d349cb08de656b68758 schema:name dimensions_id
90 schema:value pub.1037549049
91 rdf:type schema:PropertyValue
92 N12c4eaa62b964dbab130687f9f13dc85 schema:name pubmed_id
93 schema:value 28725278
94 rdf:type schema:PropertyValue
95 N5a5d2af4bd6b4cc6a06143dff2079cb6 schema:volumeNumber 10
96 rdf:type schema:PublicationVolume
97 N5f0d8f39944b464781ad1ba9c5ebcc85 schema:name Springer Nature - SN SciGraph project
98 rdf:type schema:Organization
99 N871f6be502954d13a9f9cc656f6ac322 schema:issueNumber 2
100 rdf:type schema:PublicationIssue
101 Ne22c885844414e4abc0656bf248a3ffd schema:name doi
102 schema:value 10.1007/s12254-016-0308-y
103 rdf:type schema:PropertyValue
104 Nee9675fd0802459680beb33c29bdcb51 rdf:first sg:person.01163404744.70
105 rdf:rest rdf:nil
106 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
107 schema:name Medical and Health Sciences
108 rdf:type schema:DefinedTerm
109 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
110 schema:name Oncology and Carcinogenesis
111 rdf:type schema:DefinedTerm
112 sg:journal.1039716 schema:issn 1865-5041
113 2523-2932
114 schema:name memo - Magazine of European Medical Oncology
115 schema:publisher Springer Nature
116 rdf:type schema:Periodical
117 sg:person.01163404744.70 schema:affiliation grid-institutes:grid.22937.3d
118 schema:familyName Kaczirek
119 schema:givenName Klaus
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163404744.70
121 rdf:type schema:Person
122 grid-institutes:grid.22937.3d schema:alternateName Department of Surgery and Center for Perioperative Medicine, Medical University of Vienna, Waehringer Guertel 18–20, 1090 Vienna, Austria
123 schema:name Department of Surgery and Center for Perioperative Medicine, Medical University of Vienna, Waehringer Guertel 18–20, 1090 Vienna, Austria
124 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...